<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Erythropoiesis-stimulating agents (ESAs) remain the first-line treatment of <z:hpo ids='HP_0001903'>anemia</z:hpo> in lower risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) without 5q deletion </plain></SENT>
<SENT sid="1" pm="."><plain>A preliminary report suggested that adding <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) to ESAs may improve their erythroid response, particularly in patients with high endogenous erythropoietin (EPO) level, and may improve other cytopenias </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a prospective multicenter study of EPO-beta and ATRA in anemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with marrow blasts &lt;10% and either previous ESA failure or relapse, endogenous EPO &gt;500 U/l or other cytopenia(s) (absolute neutrophilic count &lt;1.0 G/l or platelets &lt;50 G/l) </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 59 patients were evaluable after 12 weeks of treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The erythroid response rates according to IWG 2000 and 2006 criteria, respectively, were as follows: overall: 49 and 36%; patients with previous ESA failure (n=28): 43 and 32%; patients with endogenous EPO &gt;500 U/l (n=18): 11 and 19%; patients transfused &gt;2 red blood cells units/month (n=28) 43 and 39% </plain></SENT>
<SENT sid="5" pm="."><plain>Only one neutrophil, but no platelet response, and no major side effect were observed </plain></SENT>
<SENT sid="6" pm="."><plain>EPO-beta-ATRA combination appears a possible therapeutic option in <z:hpo ids='HP_0001903'>anemia</z:hpo> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> having failed an ESA alone, but not in patients with high endogenous EPO level, and does not improve <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
</text></document>